Onkotrone (Mitoxantrone Hydrochloride)

Mitoxantrone Hydrochloride, the active ingredient in Onkotrone, is an anthracene anthracenedione presented as a strength/form for intravenous use. It treats certain hematologic malignancies and solid tumors in adult patients. GNH USA supplies Onkotrone as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Onkotrone as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Mitoxantrone Hydrochloride is used in oncology for cancers that involve rapidly ​​  ​  ​  DNA replication ​ ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - Acute lymphoblastic leukemia (ALL): helps achieve remission by interfering with DNA synthesis in leukemic cells. - Acute myeloid leukemia (AML): contributes to disease control through cytotoxic activity against proliferating myeloid cells. - Metastatic breast cancer: used as part of combination regimens to reduce tumor burden. - Hormone‑refractory prostate cancer: provides palliative benefit when other therapies have failed. - High‑risk neuro‑endocrine tumors: used experimentally ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​

Mitoxantrone Hydrochloride may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset. - Fatigue: persistent tiredness affecting daily activities. - Myelosuppression: reduced blood cell counts, increasing infection risk. - Alopecia: hair loss that may be temporary. - Mucositis: inflammation of the mouth lining. - Elevated liver enzymes: mild hepatic stress.

Serious or Rare Side Effects: - Cardiotoxicity: potential for reduced heart function, especially with cumulative dosing. - Secondary leukemia: risk of developing a new hematologic malignancy. - Severe neutropenia: markedly low neutrophil count leading to serious infections. - Pulmonary fibrosis: rare scarring of lung tissue. - Acute renal failure: sudden loss of kidney function. - Anaphylactic reactions: rare severe allergic response.

Mitoxantrone Hydrochloride requires careful monitoring and patient assessment before and during therapy.

- Cardiac evaluation: perform baseline echocardiogram and monitor periodically. - Hematologic monitoring: regular complete blood counts to detect myelosuppression. - Liver function tests: assess hepatic enzymes before each cycle. - Pregnancy avoidance: contraindicated in pregnancy; use effective contraception. - Breastfeeding restriction: do not breastfeed during treatment and for a defined period after. - Store at ambient temperature: keep vials in original packaging, protect from light and moisture.

Mitoxantrone Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anthracyclines: combined use markedly increases cardiotoxic risk. - High‑dose cyclophosphamide: may amplify myelosuppression. - Live vaccines: immunosuppression can lead to uncontrolled infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Allopurinol: can affect drug metabolism and increase toxicity.